SWBIHIGH SIGNALFINANCIAL10-K

Smith & Wesson Brands experienced a substantial deterioration in profitability with net income declining meaningfully year-over-year alongside reduced revenue and compressed margins.

The company faced significant headwinds with revenue declining 11.4% while net income fell substantially more, indicating severe margin compression and operational challenges. The combination of reduced cash flow generation, lower capital investment, and increased interest expense suggests the company is managing through a difficult operating environment while potentially constraining growth investments.

Comparing 2025-06-20 vs 2024-06-20View on EDGAR →
FINANCIAL ANALYSIS

Smith & Wesson's financial performance weakened considerably, with revenue declining 11.4% to $474.7M and profitability falling substantially more due to margin compression. The company reduced capital expenditures significantly from $90.8M to $21.6M while cash declined meaningfully to $25.2M, though current liabilities also decreased by 31.1%. Inventory levels increased 37.7% despite lower sales, suggesting demand challenges, while higher interest expense and increased R&D spending further pressured profitability.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-76.2%
$90.8M$21.6M

Capex reduced 76.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
-66.1%
$39.6M$13.4M

Net income declined 66.1% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-58.5%
$60.8M$25.2M

Cash declined 58.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
-46.7%
$44.8M$23.9M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Inventory
Balance Sheet
+37.7%
$63.0M$86.7M

Inventory surged 37.7% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

R&D Expense
P&L
+31.7%
$7.3M$9.6M

R&D investment increased 31.7% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
-31.1%
$96.7M$66.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Interest Expense
P&L
+21%
$11.3M$13.7M

Interest costs rose 21% — monitor debt levels and coverage ratio in rising rate environment.

Gross Profit
P&L
-19.6%
$158.1M$127.2M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Revenue
P&L
-11.4%
$535.8M$474.7M

Revenue softened 11.4% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2025-06-20
PRIOR — 2024-06-20
ADDED
As of June 18, 2025, there were 44,309,940 sh ares of the registrant s common stock outstanding at a par value of $.001 per share.
Auditor Firm Id: 185 Auditor Name: KPMG LLP Auditor Location: Nashville, TN, USA SMITH WESSON BRANDS, INC.
This Annual Report on Form 10-K also may contain trademarks and trade names of other companies.
Risk Factors Summary Our business, operating results, and financial condition may be materially and adversely affected by the nature and impact of certain risks.
Set forth below is a summary list of the principal risk factors as of the date of the filing of this Annual Report on Form 10-K.
+7 more — sign up free →
REMOVED
As of June 18, 2024, there were outstanding 45,559,503 shares of the registrant s Common Stock, par value $.001 per share.
Auditor Firm Id: 34 Auditor Name: Deloitte Touche LLP Auditor Location: Hartford, CT, USA SMITH WESSON BRANDS, INC.
This report also may contain trademarks and trade names of other companies.
We manufacture our products at our facilities in Springfield, Massachusetts; Houlton, Maine; Deep River, Connecticut; and Maryville, Tennessee.
We also sell our manufacturing services to other businesses to attempt to level-load our factories.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →